Page 5«..4567..1020..»

Avid Bioservices Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by GHO and Ampersand

Posted: January 2, 2025 at 2:44 am

TUSTIN, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the expiration of the waiting period under the Hart-Scott-Rodino (“HSR”) Antitrust Improvements Act of 1976 with respect to the previously announced agreement for Avid to be acquired by GHO Capital Partners LLP ("GHO") and Ampersand Capital Partners (“Ampersand”).

Link:
Avid Bioservices Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by GHO and Ampersand

Posted in Global News Feed | Comments Off on Avid Bioservices Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by GHO and Ampersand

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of…

Posted: January 2, 2025 at 2:44 am

Scilex notified NASDAQ on December 30, 2024 that it has set a new record date of January 28, 2025 (the “Record Date”) for the dividend of Scilex preferred stock to Scilex’s stockholders and certain other securityholders of Scilex. Scilex notified NASDAQ on December 30, 2024 that it has set a new record date of January 28, 2025 (the “Record Date”) for the dividend of Scilex preferred stock to Scilex’s stockholders and certain other securityholders of Scilex.

Follow this link:
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of...

Posted in Global News Feed | Comments Off on Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of…

Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

Posted: January 2, 2025 at 2:44 am

Current Renovaro Chairman to Lead Subsidiary’s Development Program and Commercialization

Read the rest here:
Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

Posted in Global News Feed | Comments Off on Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV

2024 Rising Stars Shine at iC³ Summit: Celebrating Progress and Setting the Stage for 2025

Posted: January 2, 2025 at 2:44 am

DALLAS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- The 2024 Rising Stars of the life sciences and healthcare innovation sector took center stage at the iC³ Life Science Summit this year, marking another milestone in recognizing groundbreaking achievements and emerging leaders in the field. The Rising Star recognition program, a cornerstone of the iC³ Summit, continues to identify, honor, and elevate promising innovators who are driving meaningful progress in biotech, healthcare, and life sciences industries.

More here:
2024 Rising Stars Shine at iC³ Summit: Celebrating Progress and Setting the Stage for 2025

Posted in Global News Feed | Comments Off on 2024 Rising Stars Shine at iC³ Summit: Celebrating Progress and Setting the Stage for 2025

NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports

Posted: January 2, 2025 at 2:44 am

MELBOURNE, Australia and BRUSSELS, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and the Brussels-based Oncidium foundation today announce that results for the NOBLE Registry of TLX599-CDx (99mTc-iPSMA) have been published in the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) Reports.

The rest is here:
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports

Posted in Global News Feed | Comments Off on NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports

Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million

Posted: January 2, 2025 at 2:44 am

WEST LAFAYETTE, Ind., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised an additional $3.6 million in net proceeds from the optional shares in connection with its previously announced underwritten public offering of common shares. The Company issued the additional 900,000 shares at a price to the public of $4.25 per share. All the shares were offered and sold by the Company. The Company closed on the sale of the 900,000 optional shares of common stock on December 30, 2024.

Continue reading here:
Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million

Posted in Global News Feed | Comments Off on Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million

ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Posted: January 2, 2025 at 2:44 am

PRINCETON, N.J., Dec. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer; Stephen Carey, Chief Financial Officer; and Dr. Mary Pao, Chief Medical Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15pm PST/5:15pm EST, in San Francisco.

More here:
ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Posted in Global News Feed | Comments Off on ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Park Ha Biological Technology Co., Ltd. Announces Closing of $4.8 Million Initial Public Offering

Posted: January 2, 2025 at 2:44 am

Wuxi, China, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (Nasdaq: PHH) (the “Company”), a company focused on developing private skincare labels, direct skincare product sales, and franchise alliance promotions, today announced the closing of its initial public offering (the “Offering”) of 1,200,000 ordinary shares (the “Ordinary Shares”) at a public offering price of $4.00 per ordinary share. The Ordinary Shares began trading on the Nasdaq Capital Market on December 27, 2024 under the ticker symbol “PHH.”

Visit link:
Park Ha Biological Technology Co., Ltd. Announces Closing of $4.8 Million Initial Public Offering

Posted in Global News Feed | Comments Off on Park Ha Biological Technology Co., Ltd. Announces Closing of $4.8 Million Initial Public Offering

Burning Rock Announces Results of 2024 Annual General Meeting

Posted: January 2, 2025 at 2:44 am

GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company’s 2024 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions:

Follow this link:
Burning Rock Announces Results of 2024 Annual General Meeting

Posted in Global News Feed | Comments Off on Burning Rock Announces Results of 2024 Annual General Meeting

Galera Therapeutics completes acquisition of Nova Pharmaceuticals

Posted: January 2, 2025 at 2:44 am

Galera’s development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer.

Visit link:
Galera Therapeutics completes acquisition of Nova Pharmaceuticals

Posted in Global News Feed | Comments Off on Galera Therapeutics completes acquisition of Nova Pharmaceuticals

Page 5«..4567..1020..»